Climb Bio (CLYM)

• Market cap: $191M
• 1 day: -9.91%
• 5 days: -20%
• 1 month: 123.46%
• 3 months: 99%
• 6 months: 222.58%
• Year to date: 93.24%
• 1 year: 116.22%
• 5 years: -74.84%
• 10 years: -74.84%
• Sector: Healthcare
• Industry: Biotechnology

About: Climb Bio Inc is a clinical-stage biotechnology company developing therapeutics for patients with immune-mediated diseases. its product candidate, budoprutug, is an anti-CD19 monoclonal antibody that has demonstrated B-cell depletion and has the potential to treat a broad range of B-cell-mediated diseases.

Employees: 18